Univariate analysis in patients receiving tandem auto/alloHCT
| . | NRM . | Relapse . | Overall survival . | Progression free survival . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Female sex | 0.70 (0.2-2.0) | .48 | 0.83 (0.5-1.5) | .52 | 1.03 (0.5-2.0) | .92 | 0.79 (0.5-1.3) | .36 |
| Age ≥ 50 y at alloHCT | 1.23 (0.5-3.3) | .68 | 1.24 (0.7-2.2) | .47 | 1.47 (0.7-2.9) | .26 | 1.23 (0.8-2.0) | .40 |
| Age ≥ 60 y at alloHCT | 0.33 (0.0-2.5) | .28 | 1.69 (0.9-3.3) | .12 | 1.74 (0.8-3.7) | .15 | 1.26 (0.7-2.4) | .47 |
| Stage 3 | 1.75 (0.5-6.1) | .35 | 1.10 (0.6-2.1) | .76 | 1.10 (0.5-2.3) | .80 | 1.23 (0.7-2.1) | .47 |
| B2M > 3.5 mg/mL at diagnosis | 1.12 (0.4-3.5) | .85 | 2.36 (1.3-4.5) | .008 | 2.87 (1.3-6.3) | .006 | 1.98 (1.1-3.4) | .02 |
| ISS 3 | 1.91 (0.5-7.2) | .37 | 1.26 (0.5-3.1) | .62 | 1.79 (0.8-4.3) | .21 | 1.42 (0.7-3.0) | .37 |
| > 1 Prior induction therapy line | 1.41 (0.5-3.8) | .50 | 1.61 (0.9-2.9) | .13 | 2.04 (1.1-3.9) | .04 | 1.55 (0.9-2.6) | .10 |
| First therapy–autoHCT > 10 mo | 1.41 (0.5-4.0) | .52 | 2.29 (1.3-4.2) | .006 | 1.92 (1.0-3.7) | .05 | 2.02 (1.2-3.4) | .008 |
| < PR | 1.30 (0.4-3.9) | .65 | 1.45 (0.7-2.8) | .28 | 2.06 (0.9-4.9) | .10 | 1.41 (0.8-2.5) | .24 |
| Abnormal cytogenetics at autoHCT | 1.09 (0.3-4.2) | .90 | 0.87 (0.4-1.9) | .73 | 1.51 (0.7-3.4) | .32 | 0.92 (0.5-1.8) | .80 |
| B2M > 3.5 mg/mL at autoHCT | 1.13 (0.4-3.6) | .84 | 0.68 (0.3-1.5) | .32 | 0.69 (0.3-1.7) | .42 | 0.78 (0.4-1.5) | .45 |
| B2M > 3.5 mg/mL at alloHCT | 1.75 (0.5-6.3) | .42 | 1.41 (0.6-3.2) | .42 | 1.29 (0.5-3.1) | .59 | 1.50 (0.8-3.0) | .27 |
| HCT-CI > 2 | 1.32 (0.5-3.4) | .56 | 1.50 (0.8-2.7) | .18 | 1.24 (0.7-2.3) | .51 | 1.45 (0.9-2.4) | .15 |
| KS <90% at AlloHCT | 1.76 (0.6-5.0) | .28 | 3.15 (1.6-6.3) | < .001 | 2.56 (1.1-5.8) | .01 | 2.68 (1.5-4.8) | < .001 |
| Auto/alloHCT > 90 d | 2.68 (1.0-6.9) | .05 | 0.84 (0.4-1.7) | .62 | 1.55 (0.8-3.1) | .24 | 1.21 (0.7-2.1) | .50 |
| < PR at alloHCT | 1.24 (0.4-4.3) | .74 | 2.60 (1.4-4.9) | .003 | 2.44 (1.2-4.8) | .01 | 2.17 (1.2-3.8) | .007 |
| Extensive chronic GVHD* | 1.64 (0.5-4.9) | .37 | 0.91 (0.5-1.7) | .78 | 0.96 (0.5-2.0) | .91 | 1.06 (0.6-1.9) | .83 |
| Grade II-IV acute GVHD* | 3.54 (1.3-9.5) | .009 | 1.53 (0.9-2.7) | .14 | 1.81 (1.0-3.4) | .07 | 1.90 (1.2-3.1) | .009 |
| . | NRM . | Relapse . | Overall survival . | Progression free survival . | ||||
|---|---|---|---|---|---|---|---|---|
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | |
| Female sex | 0.70 (0.2-2.0) | .48 | 0.83 (0.5-1.5) | .52 | 1.03 (0.5-2.0) | .92 | 0.79 (0.5-1.3) | .36 |
| Age ≥ 50 y at alloHCT | 1.23 (0.5-3.3) | .68 | 1.24 (0.7-2.2) | .47 | 1.47 (0.7-2.9) | .26 | 1.23 (0.8-2.0) | .40 |
| Age ≥ 60 y at alloHCT | 0.33 (0.0-2.5) | .28 | 1.69 (0.9-3.3) | .12 | 1.74 (0.8-3.7) | .15 | 1.26 (0.7-2.4) | .47 |
| Stage 3 | 1.75 (0.5-6.1) | .35 | 1.10 (0.6-2.1) | .76 | 1.10 (0.5-2.3) | .80 | 1.23 (0.7-2.1) | .47 |
| B2M > 3.5 mg/mL at diagnosis | 1.12 (0.4-3.5) | .85 | 2.36 (1.3-4.5) | .008 | 2.87 (1.3-6.3) | .006 | 1.98 (1.1-3.4) | .02 |
| ISS 3 | 1.91 (0.5-7.2) | .37 | 1.26 (0.5-3.1) | .62 | 1.79 (0.8-4.3) | .21 | 1.42 (0.7-3.0) | .37 |
| > 1 Prior induction therapy line | 1.41 (0.5-3.8) | .50 | 1.61 (0.9-2.9) | .13 | 2.04 (1.1-3.9) | .04 | 1.55 (0.9-2.6) | .10 |
| First therapy–autoHCT > 10 mo | 1.41 (0.5-4.0) | .52 | 2.29 (1.3-4.2) | .006 | 1.92 (1.0-3.7) | .05 | 2.02 (1.2-3.4) | .008 |
| < PR | 1.30 (0.4-3.9) | .65 | 1.45 (0.7-2.8) | .28 | 2.06 (0.9-4.9) | .10 | 1.41 (0.8-2.5) | .24 |
| Abnormal cytogenetics at autoHCT | 1.09 (0.3-4.2) | .90 | 0.87 (0.4-1.9) | .73 | 1.51 (0.7-3.4) | .32 | 0.92 (0.5-1.8) | .80 |
| B2M > 3.5 mg/mL at autoHCT | 1.13 (0.4-3.6) | .84 | 0.68 (0.3-1.5) | .32 | 0.69 (0.3-1.7) | .42 | 0.78 (0.4-1.5) | .45 |
| B2M > 3.5 mg/mL at alloHCT | 1.75 (0.5-6.3) | .42 | 1.41 (0.6-3.2) | .42 | 1.29 (0.5-3.1) | .59 | 1.50 (0.8-3.0) | .27 |
| HCT-CI > 2 | 1.32 (0.5-3.4) | .56 | 1.50 (0.8-2.7) | .18 | 1.24 (0.7-2.3) | .51 | 1.45 (0.9-2.4) | .15 |
| KS <90% at AlloHCT | 1.76 (0.6-5.0) | .28 | 3.15 (1.6-6.3) | < .001 | 2.56 (1.1-5.8) | .01 | 2.68 (1.5-4.8) | < .001 |
| Auto/alloHCT > 90 d | 2.68 (1.0-6.9) | .05 | 0.84 (0.4-1.7) | .62 | 1.55 (0.8-3.1) | .24 | 1.21 (0.7-2.1) | .50 |
| < PR at alloHCT | 1.24 (0.4-4.3) | .74 | 2.60 (1.4-4.9) | .003 | 2.44 (1.2-4.8) | .01 | 2.17 (1.2-3.8) | .007 |
| Extensive chronic GVHD* | 1.64 (0.5-4.9) | .37 | 0.91 (0.5-1.7) | .78 | 0.96 (0.5-2.0) | .91 | 1.06 (0.6-1.9) | .83 |
| Grade II-IV acute GVHD* | 3.54 (1.3-9.5) | .009 | 1.53 (0.9-2.7) | .14 | 1.81 (1.0-3.4) | .07 | 1.90 (1.2-3.1) | .009 |
95% CI indicates 95% confidence interval; B2M, β -2-microglobulin; and ISS, International Staging Score.
GVHD was considered a time-dependent covariate.